ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TIVICAY
Viral infections
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TIVICAY Rx

Generic Name and Formulations:
Dolutegravir 10mg, 25mg, 50mg; tabs.

Company:
ViiV Healthcare

Therapeutic Use:

Indications for TIVICAY:

In combination with other antiretroviral agents for the treatment of HIV-1 infection.

Adult:

Treatment-naïve or treatment-experienced INSTI-naïve: 50mg once daily; when concomitant with certain UGT1A or CYP3A inducers: 50mg twice daily. INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50mg twice daily.

Children:

<30kg or INSTI-experienced with documented or clinically suspected resistance to other INSTIs (raltegravir, elvitegravir): not established. Treatment-naïve or treatment-experienced INSTI-naïve: (30–<40kg): 35mg once daily; (≥40kg): 50mg once daily. If concomitant with certain UGT1A or CYP3A inducers, increase weight-based dose to twice daily.

Contraindications:

Concomitant dofetilide.

Warnings/Precautions:

Discontinue if hypersensitivity reactions develop. Increased risk for worsening/development of elevated transaminases in patients with hepatitis B or C; monitor LFTs prior to starting and during therapy. Severe hepatic impairment: not recommended. INSTI-experienced patients (with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance) with severe renal impairment: decrease in dolutegravir concentrations may result in loss of efficacy and development of resistance. Dialysis. Elderly. Pregnancy. Nursing mothers: not recommended.

Interactions:

May be affected by drugs that induce or inhibit UGT1A1, UGT1A3, UGT1A9, BCRP, and P-gp enzymes or transporters. Avoid concomitant nevirapine, oxcarbazepine, phenytoin, phenobarbital, St. John’s wort. Avoid etravirine unless coadministered with atazanavir/ritonavir, darunavir/ritonavir, or lopinavir/ritonavir. Concomitant efavirenz, fosamprenavir/ritonavir, tipranavir/ritonavir, rifampin, or carbamazepine: adjust dose (see Adults, Children). Concomitant cation-containing antacids, laxatives, sucralfate, oral iron/calcium supplements, and buffered drugs: give dolutegravir 2hrs before or 6hrs after. Limit concomitant metformin dose to 1000mg/day; adjust metformin dose when stopping dolutegravir; monitor closely.

Pharmacological Class:

HIV-1 integrase strand transfer inhibitor (INSTI).

Adverse Reactions:

Insomnia, fatigue, headache; immune reconstitution syndrome, fat redistribution, lab abnormalities, hypersensitivity reactions.

Note:

Register pregnant patients exposed to dolutegravir by calling (800) 258-4263.

Generic Availability:

NO

How Supplied:

Tabs—30

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs